Corneal Alternatives: Non-Transplant Vision Correction
New Data on Ranibizumab Biosimilar Demonstrate noninferiority in DME
Table of Contents
Recent findings presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 annual meeting offer compelling evidence supporting the efficacy and safety of a ranibizumab biosimilar (Xbivio, Formosa Pharmaceuticals) in treating diabetic macular edema (DME). The data, stemming from the Phase 3 ARTEMIS-DME study, demonstrate noninferiority to the reference ranibizumab (Lucentis, Genentech) through 52 weeks.Agarwal, assaf, Holladay and Parker report no relevant financial disclosures.
ARTEMIS-DME: A Detailed Look at the Study
The ARTEMIS-DME trial was a randomized, double-masked, multicenter study designed to evaluate the comparability of Xbivio to Lucentis in patients with DME. Here’s a breakdown of the key aspects:
Study Design: 300 participants with DME were randomized 1:1 to receive either Xbivio or Lucentis.
Primary Endpoint: The primary endpoint was the change in best-corrected visual acuity (BCVA) from baseline to week 52.
Secondary Endpoints: Secondary endpoints included changes in central retinal thickness (CRT) and the proportion of patients gaining ≥15 letters in BCVA.
Patient Population: Participants had a mean age of approximately 62 years and a mean duration of diabetes of around 12 years.
Key findings: Noninferiority confirmed
The results of the ARTEMIS-DME study were highly encouraging.
BCVA: Xbivio demonstrated noninferiority to Lucentis in the change in BCVA from baseline to week 52. This means the biosimilar performed similarly to the original drug in terms of visual acuity improvement. CRT: Both Xbivio and Lucentis considerably reduced CRT from baseline to week 52, with no statistically notable difference between the two groups. This indicates both treatments effectively reduced macular swelling.
Gaining Visual Acuity: A comparable proportion of patients in both groups achieved a gain of ≥15 letters in BCVA, further supporting the biosimilar’s efficacy. Safety Profile: The safety profiles of Xbivio and Lucentis were similar, with no unexpected adverse events observed. This is a crucial aspect of biosimilar growth, ensuring patients can trust the safety of the option treatment.
What Does This Mean for Patients and Practitioners?
The ARTEMIS-DME study provides strong evidence that Xbivio is a viable and effective treatment option for DME.This has several important implications:
increased Access: Biosimilars generally offer a more affordable alternative to originator biologics, possibly increasing access to treatment for a wider range of patients.
Treatment Options: the availability of Xbivio expands the treatment options available to ophthalmologists for managing DME.
Cost Savings: Lower costs associated with biosimilars can contribute to overall healthcare savings.
The Growing Role of Biosimilars in Ophthalmology
Biosimilars are playing an increasingly important role in ophthalmology, offering cost-effective alternatives to established biologics.Ranibizumab biosimilars, like Xbivio, are at the forefront of this trend. As more biosimilars become available, we can expect to see:
Greater Competition: Increased competition among manufacturers, potentially driving down prices further.
Expanded Research: Continued research to evaluate the long-term efficacy and safety of biosimilars.
Improved Patient Outcomes: Ultimately, the goal is to improve patient outcomes by making effective treatments more accessible and affordable.
If you’re living with DME, talk to your ophthalmologist about whether a ranibizumab biosimilar like Xbivio might be a suitable treatment option for